Long-Term Prognostication for 20 114 Women With Small and Node-Negative Breast Cancer (T1abN0)
Open Access
- 26 September 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 5 (1) , pkaa084
Abstract
Background: Although small, node-negative breast cancer (ie, T1abN0) constitutes 20% of all newly diagnosed breast cancers, data on prognosis and prognostic factors are limited. Methods: We conducted a population-based cohort study including 20 114 Swedish women treated for T1abN0 breast cancer from 1977 onward. Patient and tumor data were collected from Swedish breast cancer registries. Cohort subjects were followed through linkage to the Cause of Death Register. We calculated the cumulative incidence of breast cancer–specific and overall death and used Cox regression to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). Results: During a median follow-up of 9.1 years (range = 0-38), 915 women died of breast cancer and 5416 of any cause. The 10-, 20-, and 30-year cumulative incidences of breast cancer death were 3.4% (95% CI = 3.1% to 3.7%), 7.6% (95% CI = 7.1% to 8.2%), and 10.5% (95% CI = 9.6% to 11.4%), respectively. The multivariable hazard ratios and 95% confidence intervals of breast cancer death were 0.92 (95% CI = 0.88 to 0.97) for each additional calendar year of diagnosis, 4.38 (95% CI = 2.79 to 6.87) for grade 3 vs grade 1 tumors, 0.43 (95% CI = 0.31 to 0.62) for progesterone receptor–positive vs progesterone receptor–negative disease, and 2.01 (95% CI = 0.99 to 4.07) for HER2-positive vs HER2-negative disease. Women with grade 3 vs grade 1 tumors had a 56% increased risk of death from any cause (HR = 1.56, 95% CI = 1.30 to 1.88). Conclusions: The risk of breast cancer death in T1abN0 disease continues to increase steadily beyond 10 years after diagnosis, has improved over time, and varies substantially by tumor characteristics.Keywords
Funding Information
- Swedish Breast Cancer Association and the Swedish Society of Medicine (SLS-502451)
This publication has 27 references indexed in Scilit:
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trialsThe Lancet, 2012
- Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypesBreast Cancer Research and Treatment, 2011
- High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2–Positive, Node-Negative Tumors 1 cm or SmallerJournal of Clinical Oncology, 2009
- The completeness of the Swedish Cancer Register – a sample survey for year 1998Acta Oncologica, 2009
- Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast CancersJournal of Clinical Oncology, 2008
- Overall Survival and Cause-Specific Mortality of Patients With Stage T1a,bN0M0 Breast CarcinomaJournal of Clinical Oncology, 2007
- Prognosis and Management of Patients With Node-Negative Invasive Breast Carcinoma That Is 1 cm or Smaller in Size (stage 1; T1a,bN0M0): A Review of the LiteratureJournal of Clinical Oncology, 2006
- Late mortality from pT1N0M0 breast carcinomaCancer, 1999
- Determination of Cause of Death Among Breast Cancer Cases in the Swedish Randomized Mammography Screening Trials: A comparison between official statistics and validation by an endpoint committeeActa Oncologica, 1995
- Breast cancer treatment and natural history: new insights from results of screeningThe Lancet, 1992